Introduction
The completion of human genome sequencing and the subsequent gene annotations, together with a rapid development of high throughput screening technologies, such as DNA microarrays, have made it possible to perform genome-scale expression profiling and comparative genomic hybridizations (CGHs) in various cancer models. The elucidation of gene copy number variations in several cancer genomes is generating very informative results. Metaphase chromosome CGH and the recent introduction of BAC and especially cDNA microarray-based CGHs (aCGH) (1) have greatly contributed to the identification of chromosome aberrations and of amplified and deleted genes in gastric cancer tissues and cell lines (2) (3) (4) (5) (6) (7) (8) (9) .
Chromosome 7 has often been reported as containing regions undergoing genetic changes or unstable regions in various cancer models including gastric cancer (3, 6, (10) (11) (12) (13) (14) (15) (16) (17) . However, there have been no systematic searches for individual genes undergoing copy number increases or amplifications, since most of the previously mentioned studies employed metaphase chromosome or BAC array CGHs. Human chromosome 7 is ~159 Mb in length, contains 1150 genes and 940 'pseudogenes', a number of which have been implicated in a diversity of human diseases, including cystic fibrosis, deafness, B-cell lymphoma and cancers (18) . Chromosome 7 contains known oncogenes that exhibit gene amplifications, including epidermal growth factor receptor (EGFR, located at 7p12), hepatocyte growth factor (HGF, 7q21.1) and met proto-oncogene (MET/HGFR, 7q31) (19) (20) (21) (22) (23) . Since one of the most frequent mechanisms of oncogenic activation is gene amplification, it is of utmost importance to be able to identify all the possible collection of genes that are amplified in tumor tissues of a given cancer model. We previously reported a cDNA microarray-based CGH analysis of gastric cancer, in which gene copy number increases at chromosome 20 were identified (9) and the relationship between copy number changes and gene expression was explored (24) . In the current analysis, we focused on the gene amplification at chromosome 7 of the gastric cancer genome, which could potentially lead to the identification of novel candidate oncogenes.
Materials and methods
Gastric cancer tissues and aCGH. Gastric cancer microarray CGH experiments were described previously (9) . Briefly, 30 pairs of normal gastric and corresponding tumor tissues were used for the experiment with patient consent and approval of the supervisory committee of the Yonsei University College of Medicine. The tumor tissues used for the experiments contained at least 70% tumor content as was confirmed by a pathologist. Tissues were kept at -80˚C after surgery, ground to powder using liquid nitrogen, pestle and mortar, and the genomic DNA was prepared using the phenol/ chloroform/isoamylalcohol method. CGH experiments were performed using 17K cDNA microarrays (GenomicTree, Daejeon, Korea), which have been employed in several experiments and have produced reliable data sets (25) (26) (27) . The microarrays contain PCR products from 17,000 Ultimate™ ORF clones, which are full-insert sequenced and were confirmed for a 100% match to known amino acid sequences by the manufacturer (Invitrogen, Carlsbad, CA). The OmniGrid™ microarrayer (GeneMachines Inc., San Carlos, CA) and CMT-GAPS™ glass slides were used for printing the microarrays (Corning, Charlotte, NC). Genomic DNA (6 μg) was DpnII-digested, purified using a QIAquick PCR purification kit (Qiagen, Düsseldorf, Germany) and was subjected to fluorescent labeling using a Bioprime labeling kit (Invitrogen). The reaction mixtures were incubated at 37˚C for 2 h in the dark and were quenched by adding 5 μl of 0.5 M EDTA, pH 8.0. The microarray slides were incubated in 3.5X SSC, 0.1% SDS with 10 mg/ml BSA for 1 h at 42˚C for blocking. The genomic DNA from the normal and tumor tissues was labeled with Cy3-dCTP and Cy5-dCTP, respectively. Cy3-and Cy5-labeled DNAs from the tissue samples were mixed with 30 μg human Cot-1 DNA, 20 μg poly(dA)-poly(dT) oligonucleotides and 100 μg yeast tRNA. A Microcon-30 filter (Amicon, Bedford, MA) was used to purify and concentrate the hybridization mixture, which was then adjusted to the final concentration of 3.5X SSC and 0.3% SDS in a volume of 60 μl. Following denaturation at 100˚C for 1.5 min and pre-annealing at 37˚C for 30 min, the labeled DNA mixture was applied to the cDNA microarray and incubated at 65˚C for 20-30 h. The slides were then washed for 2 min each in 0.5X SSC/0.01% SDS, 0.06X SSC/0.01% SDS, and 0.05X SSC, consecutively, at room temperature and spun-dried. The microarray slides were scanned using a GenePix 4000B scanner (Axon Instruments, Foster City, CA), and the data were saved in a Gene Pix Result (GPR) format. The microarray dataset was deposited in the ArrayExpress database (www.ebi.ac.uk).
Data analysis. Copy number change analysis for the genes located on chromosome 20 and the genome-scale correlation analysis of copy number change and gene expression from the same data set were recently published (9, 24) . In this report, gene copy number increases for genes located on chromosome 7 are shown in detail. Previously, we reported that 1,780 genes (probes with unique GB acc nos) showed copy number increases in gastric cancer, when 30 normal and 30 tumor tissues were analyzed by aCGH on 17K cDNA microarrays. From 1,780 probes with unique GB acc nos, copy change ratios for the 104 probes on chromosome 7 were extracted. After Source annotation (http://genome-www5. stanford.edu/cgi-bin/source/sourceSearch), 90 genes with reliable information including gene symbols, Unigene IDs and cytoband information were selected. For the visualization of the copy change data in CGH-Explorer (28), which requires nucleotide position information to plot the relative distance of the genes in the analysis, the absolute nucleotide positions for the start point of each gene were obtained from Ensembl (www.ensembl.org). The gene copy number changes detected by the current aCGH were validated by real-time PCR with tissue genomic and also by fluorescent in situ hybridization (24) . Copy number increases were defined as those showing log 2 (Cy5/Cy3) ≥0.58 (~1.5-fold).
Results and discussion
Global view of gene amplifications on chromosome 7 of the gastric cancer genome. When 30 pairs of normal and tumor tissues were tested for copy number variations in gastric cancer using 17K cDNA array in a direct design (normal-Cy3 and tumor-Cy5), it was shown that 1,780 genes were undergoing copy number increases (gene amplifications) in gastric cancer. Of these, 90 chromosome 7-specific genes were used for further analysis (Materials and methods). First, to look at the empirical distribution of the copy change ratios for the 90 genes, a density histogram of normal distribution was drawn (Fig. 1A ). Since we were testing only the amplified genes, and not the deleted genes, the histogram showed skewness to the positive log ratio values in reference to 0 ('skew': 1.598) and also showed a positive kurtosis, in that there was a heavier tail than for a normal distribution ('kurt': 7.515). The mean log 2 (Cy5/Cy3) was 0.254 with a variance of 0.283 for the dataset, and it matched our definition of copy number increase or gene amplification; in control CGH experiments employing two normal gastric tissues from male and female subjects (XY and XX), variations in log 2 (Cy5/Cy3) ratios between -0.3 and +0.3 were observed for the genes located on autosomes (26) , and adding one standard deviation we defined copy number increase in this data set as those with log 2 (Cy5/Cy3) ≥0.58 (9) .
To visualize the overall distribution of genes and their ratios, additional graphs were generated. The 90 genes were given their absolute position from pter to qter of chromosome 7 in nucleotide numbers and were drawn in their relative positions on chromosome 7. A gene density map (Fig. 1B) shows a distribution of genes being tested on a chromosome. In the case of chromosome 7, 90 genes were evenly distributed along chromosome 7. When the number of the amplified genes was plotted on the cytoband location of chromosome 7, it was shown that amplified genes were centered between p11~p22 and q21~q36 (Fig. 1C) . A moving average plot (Fig. 1D) shows 30 copy number change profiles representing 30 experiments (patients) over 90 genes, also along the chromosomal locations. Some genes showing a high degree of amplification, or high log ratios, are shown, including anterior gradient homolog 2 (AGR2), acyloxyacyl hydrolase (AOAH), LanC lantibiotic synthetase component C-like 2 (bacterial) (LANCL2) and split hand/foot malformation (ectrodactyly) type 1 (SHFM1). Although some public databases indicated that LANCL2 is located at 7q31.1-q31.33, the Ensembl database with the latest update on human genome sequencing information showed that the starting and stop positions of the LANCL2 genomic clone are Table I . Amplified genes in chromosome 7 of the human gastric cancer genome. 55,400,635 and 55,468,929 nucleotides, respectively, from the pter of the chromosome, which corresponds to a cytoband location of 7p11.2. There were differences even for the 4 amplified genes shown as an example in Fig. 1C . While all 4 genes of AGR2, AOAH, LANCL2 and SHFM1 showed a high level of gene copy number increase, log 2 (Cy5/Cy3) ≥2, indicating >4-fold amplification, only the AOAH gene was being amplified with a high frequency. In fact AOAH represented the most frequently copy number increased gene on chromosome 7, being amplified in 25 of the 30 tested patients (~83% frequency), while SHFM1 showed the highest increase in ratio (8-fold increase in tumor tissue) in Table I . Continued.
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a Ratio refers to fold increases. Genes with log 2 (Cy5-tumor/Cy3-normal) ≥0.58 are listed in the order of fold change.
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only one of the patients (Table I) . When all 30 ratios for each of the 90 genes were plotted, it showed that AOAH had more amplified cases (Fig. 1D) .
Amplified genes of chromosome 7 of the gastric cancer genome. In this study, we identified a total of 90 genes that were copy number increased in chromosome 7 with varying frequencies (Table I ). The list contained such genes as wingless-type MMTV integration site family member 2 (WNT2), a gene previously identified as an amplified protooncogene in gastric adenocarcinoma (11) . We also recently identified genes that showed mRNA expression and copy number change profiles in a highly correlated manner (24) . Of the 90 genes shown in Table I , five known genes and one Est were among the 158 genes that demonstrated correlation coefficients >0.6 between gene copy change and mRNA expression. For these genes, the copy number increase directly influenced the overall mRNA production from the corresponding gene. (29) . This gene is a target in the clinical study of multidrug resistance (MDR1) gene therapy, with promising initial results in breast cancer (30) , but conflicting results in other cases (31) . Other members of the 90 genes identified as being amplified in the gastric cancer genome in this report have also been targets of therapeutic development in other diseases (Table II) . Genes on chromosome 7 have been implicated in various human diseases including cancer. The identification of chromosome 7-specific gene amplifications is useful data not only for gastric cancer research, but also for researching other human diseases. Table II . Amplified genes that are also therapeutic targets in other diseases. 
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Genes listed in Table I were searched for along with drugs/ligands in the Therapeutic Target Database maintained by Dr Chen Yuzong at the National University of Singapore (32) , and 4 target genes were identified and listed. Neuropeptide Y is a target drug currently under investigation.
